5-氯-2,3-二氟-6-碘吡啶 | 406676-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯-2,3-二氟-6-碘吡啶
• 英文名称: 3-chloro-5,6-difluoro-2-iodopyridine
• 英文别名: 5-chloro-2,3-difluoro-6-iodopyridine
• CAS: 406676-37-7
• 化学式: C₅HClF₂IN
• 分子量: 275.424
• InChiKey: WLZNIHNNTLKZQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3H-咪唑并[4,5-b]吡啶 、 5-氯-2,3-二氟-6-碘吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 6-(3-chloro-5,6-difluoropyridin-2-yl)-3-methyl-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  [EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  [FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE

  摘要：

  本发明涉及吡唑-4-基吡啶化合物，这些化合物是M4肌制酸乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在治疗或预防M4肌制酸乙酰胆碱受体参与的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗M4肌制酸乙酰胆碱受体参与的疾病中的用途。

  公开号：

  WO2019005587A1
• 作为产物：
  描述：

  5-氯-2,3-二氟-4-碘吡啶 在 2,2,6,6-tetramethylpiperidinyl-lithium 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以46%的产率得到5-氯-2,3-二氟-6-碘吡啶
  参考文献：
  名称：

  区域化学灵活性：2,3,5-三卤吡啶在 4 位或 6 位的选择性官能化

  摘要：

  使用 2,3,5-三氯吡啶、3,5-二氯-2-氟吡啶和 5-氯-2,3-二氟吡啶作为底物进行去质子化研究。与二异丙基氨基锂 (LDA) 反应后，去质子化仅发生在 4 位。随后的羧化和碘化产生酸和 4-碘吡啶。后者的曝光。对锂 2,2,6,6-四甲基哌啶 (LITMP) 造成去质子化并立即导致碘迁移。中间体用干冰捕获以提供羧酸。中和后得到6-碘吡啶。这些化合物。当用异丙基氯化镁处理时，很容易将重卤素换成金属。通过这种方式，可以在 6 位选择性地引入官能团。常规使用二氧化碳作为模型亲电试剂，形成了三卤代吡啶羧酸，目前尚不清楚，这将为药物研究提供有价值的新构建块。此外，2-位卤素的选择性亲核置换可以产生各种各样的新结构。[在 SciFinder (R) 上]

  DOI：

  10.1002/1099-0690(200112)2001:23<4533::aid-ejoc4533>3.0.co;2-1

文献信息

• [EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019005588A1

  公开（公告）日：2019-01-03

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑并[4,3-b]吡啶化合物，其为M4毒蕈碱型乙酰胆碱受体的变构调节剂。本发明还涉及在可能治疗或预防神经和精神障碍以及涉及M4毒蕈碱型乙酰胆碱受体的疾病中使用所述化合物。本发明还涉及包含这些化合物的组合物。本发明还涉及在可能预防或治疗涉及M4毒蕈碱型乙酰胆碱受体的疾病中使用这些组合物。
• [EN] 3- (1H-PYRAZOL-4-YL) PYRIDINEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2017107089A1

  公开（公告）日：2017-06-29

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑-4-基吡啶化合物，其为M4肌碱乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在的治疗或预防神经系统和精神疾病中的用途，其中M4肌碱乙酰胆碱受体参与其中。本发明还涉及含有这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗M4肌碱乙酰胆碱受体参与的疾病中的用途。
• 3-(1H-PYRAZOL-4-YL) PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  申请人：MERCK SHARP & DOHME CORP.

  公开号：EP3769763A1

  公开（公告）日：2021-01-27

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑-4-基吡啶化合物，它们是 M4 肌乙酰胆碱受体的异位调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10933056B2

  公开（公告）日：2021-03-02

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑-4-基吡啶化合物，它们是 M4 肌乙酰胆碱受体的异位调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3393472A1

  公开（公告）日：2018-10-31